Couetil J P, Houssin D P, Soubrane O, Chevalier P G, Dousset B E, Loulmet D, Achkar A, Tolan M J, Amrein C I, Guinvarch A
Department of Cardiovascular Surgery, Broussais Hospital, Paris, France.
J Thorac Cardiovasc Surg. 1995 Nov;110(5):1415-22; discussion 1422-3. doi: 10.1016/s0022-5223(95)70064-1.
Patients with cystic fibrosis who have end-stage respiratory failure and associated liver cirrhosis have been considered poor candidates for lung transplantation because of high morbidity and mortality resulting from hepatic insufficiency after the operation. Since April 1989, our policy has been to combine heart-lung or lung and liver transplantation in this group of patients. Between June 1990 and March 1995, among 25 patients accepted in the program for combined transplantation, nine died awaiting transplantation and 10 underwent one of the following procedures: heart-lung-liver transplantation (n = 5), en bloc double lung-liver transplantation (n = 1), sequential double lung-liver transplantation (n = 3), and bilateral lobar lung transplantation from a split left lung and reduced liver transplantation (n = 1). There were 5 male and 5 female patients. The ages of the recipients ranged from 10 to 24 years. Mean forced expiratory volume in 1 second was 29% and mean forced vital capacity was 35% of predicted values. All patients were infected with resistant Pseudomonas, three with Pseudomonas cepaceia, and two patients had Aspergillus species in addition. All patients had severe cirrhosis with portal hypertension. Four patients had a history of esophageal variceal bleeding and two had had previous portosystemic shunts. The operation was performed as a two-stage procedure, the intrathoracic operation being completed before the abdominal stage was begun. Cardiopulmonary bypass was used in all patients because of poor clinical condition. Immunosuppression consisted of azathioprine, cyclosporine, and prednisone, as for isolated lung transplantation. There were two perioperative deaths, one caused by primary liver failure and the second by early lung dysfunction. For the first 3 months after transplantation pulmonary infection was the most common cause of morbidity. Other complications included tracheal stenosis (n = 1), bronchial stenosis (n = 1), biliary stricture (n = 2), and severe ascites (n = 3). All were successfully treated. Obliterative bronchiolitis developed in three patients. This was stabilized with FK 506 in two patients; the other patient underwent retransplantation at 38 months but eventually died of bleeding. Actuarial survival was 70% at 1 year and remained unchanged at 3 years. Significant functional improvement was observed in all survivors. For patients who have chronic respiratory failure with advanced cirrhosis, lung transplantation combined with liver transplantation can be performed with a satisfactory outcome.
患有终末期呼吸衰竭及相关肝硬化的囊性纤维化患者,由于术后肝功能不全导致的高发病率和死亡率,一直被认为是肺移植的不良候选者。自1989年4月以来,我们的政策是对这组患者进行心肺联合或肺与肝联合移植。1990年6月至1995年3月期间,在接受联合移植项目的25例患者中,9例在等待移植过程中死亡,10例接受了以下手术之一:心肺肝联合移植(n = 5)、整块双肺-肝移植(n = 1)、序贯双肺-肝移植(n = 3)以及取自劈开左肺的双侧肺叶移植和减体积肝移植(n = 1)。有5例男性和5例女性患者。受者年龄在10至24岁之间。1秒用力呼气量平均为预测值的29%,用力肺活量平均为预测值的35%。所有患者均感染了耐药铜绿假单胞菌,3例感染洋葱伯克霍尔德菌,2例还感染了曲霉菌。所有患者均有严重肝硬化伴门静脉高压。4例有食管静脉曲张出血史,2例曾行门体分流术。手术分两阶段进行,胸腔内手术在腹部手术开始前完成。由于临床状况不佳,所有患者均使用了体外循环。免疫抑制方案与单纯肺移植相同,包括硫唑嘌呤、环孢素和泼尼松。围手术期有2例死亡,1例死于原发性肝功能衰竭,另1例死于早期肺功能障碍。移植后的前3个月,肺部感染是最常见的发病原因。其他并发症包括气管狭窄(n = 1)、支气管狭窄(n = 1)、胆管狭窄(n = 2)和严重腹水(n = 3)。所有这些并发症均成功治愈。3例患者发生闭塞性细支气管炎。2例患者使用FK 506后病情稳定;另1例患者在38个月时接受了再次移植,但最终死于出血。1年时的实际生存率为70%,3年时保持不变。所有存活者均观察到显著的功能改善。对于患有慢性呼吸衰竭并伴有晚期肝硬化的患者,肺移植联合肝移植可以取得令人满意的结果。